Pfizer Inc.(PFE)Earnings, Financials & Key Ratios

PFE•NYSE

$26.44

$150.4B mkt cap·19.4× P/E·Price updated May 6, 2026

SectorHealthcare IndustryLarge Pharma Sub-IndustryVaccines and plasma-derived therapies

AboutPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.Show more

Revenue$62.58B-1.6%
EBITDA$20.34B-13.4%
Net Income$7.77B-3.1%
EPS (Diluted)1.36-3.5%
Gross Margin70.33%+6.9%
EBITDA Margin32.51%-12.0%
Operating Margin24.67%-4.8%
Net Margin12.42%-1.5%
ROE8.87%-1.7%
ROIC7.53%-5.1%
Debt/Equity0.78+2.6%
Interest Coverage3.82+6.1%

Analysis→Technical→

PFE Key Insights

Pfizer Inc. (PFE) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓15 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 17.4%

✗Weaknesses

✗Dividend payout exceeds 100% of earnings

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

PFE Price & Volume

Pfizer Inc. (PFE) stock price & volume — 10-year historical chart

Loading chart...

PFE Growth Metrics

Pfizer Inc. (PFE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years2.51%

5 Years8.48%

3 Years-14.56%

TTM1.36%

Profit CAGR

10 Years1.1%

5 Years-3.24%

3 Years-37.2%

TTM-4.78%

EPS CAGR

10 Years2.02%

5 Years-3.51%

3 Years-37.12%

TTM-5.05%

Return on Capital

10 Years10.75%

5 Years12.56%

3 Years7.22%

Last Year9.04%

PFE Recent Earnings

Pfizer Inc. (PFE) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)

Q2 2026Latest

May 5, 2026

EPS

$0.48

Est $0.71

-32.4%

Revenue

$14.5B

Est $13.8B

+4.4%

Q1 2026

Feb 3, 2026

EPS

$0.66

Est $0.57

+16.4%

Revenue

$17.6B

Est $16.8B

+4.2%

Q4 2025

Nov 4, 2025

EPS

$0.87

Est $0.63

+37.4%

Revenue

$16.7B

Est $16.5B

+0.9%

Q3 2025

Aug 5, 2025

EPS

$0.78

Est $0.58

+34.5%

Revenue

$14.7B

Est $13.6B

+8.1%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$0.48vs $0.71-32.4%	$14.5Bvs $13.8B+4.4%
Q1 2026	Feb 3, 2026	$0.66vs $0.57+16.4%	$17.6Bvs $16.8B+4.2%
Q4 2025	Nov 4, 2025	$0.87vs $0.63+37.4%	$16.7Bvs $16.5B+0.9%
Q3 2025	Aug 5, 2025	$0.78vs $0.58+34.5%	$14.7Bvs $13.6B+8.1%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
JNJJohnson & JohnsonDirect Competitor	543.64B	225.59	38.96	4.3%	27.26%	31.69%	3.65%	0.51
MRKMerck & Co., Inc.Direct Competitor	279.49B	113.16	15.54	1.18%	28.12%	36.14%	4.42%	0.96
ABBVAbbVie Inc.Direct Competitor	364.63B	206.15	86.98	8.57%	6.91%	62.15%	4.89%
LLYEli Lilly and CompanyDirect Competitor	933.66B	988.19	43.06	44.7%	34.98%	101.17%	0.96%	1.60
BMYBristol-Myers Squibb CompanyDirect Competitor	116.22B	56.92	16.50	-0.22%	15.01%	38.96%	11.05%	2.55
AZNAstraZeneca PLCDirect Competitor	280.97B	181.24	27.71	8.63%	17.19%	22.24%	4.19%	0.61
NVSNovartis AGDirect Competitor	277.63B	145.50	20.24	5.97%	24.14%	31.42%	6.37%	0.80
AMGNAmgen Inc.Product Competitor	177.87B	329.59	23.16	9.92%	20.95%	89.41%	4.55%	6.31

Compare PFE vs Peers

Pfizer Inc. (PFE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs JNJ

Most directly comparable listed peer for PFE.

Scale Benchmark

vs LLY

Larger-name benchmark to compare PFE against a more recognizable public peer.

Peer Set

Compare Top 5

vs JNJ, MRK, ABBV, LLY

PFE Income Statement

Pfizer Inc. (PFE) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	52.55B	53.65B	41.17B	41.65B	81.29B	100.33B	59.55B	63.63B	62.58B	63.31B
Revenue Growth %	-0.53%	2.1%	-23.25%	1.16%	95.16%	23.43%	-40.64%	6.84%	-1.65%	1.36%
Cost of Goods Sold	15.78B	16.01B	12.62B	11.77B	34.41B	38.24B	29.21B	21.78B	18.57B	19.41B
COGS % of Revenue	30.03%	29.84%	30.66%	28.26%	42.33%	38.11%	49.05%	34.23%	29.67%	-
Gross Profit	36.77B▲ 0%	37.64B▲ 2.4%	28.55B▼ 24.2%	29.88B▲ 4.7%	46.88B▲ 56.9%	62.09B▲ 32.5%	30.34B▼ 51.1%	41.85B▲ 37.9%	44.01B▲ 5.2%	43.91B▲ 0%
Gross Margin %	69.97%	70.16%	69.34%	71.74%	57.67%	61.89%	50.95%	65.77%	70.33%	69.35%
Gross Profit Growth %	-0.27%	2.37%	-24.15%	4.66%	56.88%	32.46%	-51.14%	37.92%	5.18%	-
Operating Expenses	22.38B	22.35B	21.04B	20.8B	26.08B	24.54B	25.05B	25.36B	28.58B	29.06B
OpEx % of Revenue	42.59%	41.66%	51.1%	49.93%	32.09%	24.46%	42.06%	39.86%	45.67%	-
Selling, General & Admin	14.73B	14.38B	12.67B	11.4B	12.25B	13.12B	14.47B	14.73B	13.35B	13.28B
SG&A % of Revenue	28.04%	26.81%	30.78%	27.37%	15.07%	13.07%	24.3%	23.15%	21.33%	-
Research & Development	7.64B	7.97B	8.36B	9.39B	13.83B	11.43B	10.58B	10.74B	11.98B	12.42B
R&D % of Revenue	14.55%	14.85%	20.31%	22.56%	17.01%	11.39%	17.76%	16.88%	19.14%	-
Other Operating Expenses	0	0	0	0	0	0	0	-105M	3.25B	3M
Operating Income	14.39B▲ 0%	15.29B▲ 6.2%	7.51B▼ 50.9%	9.09B▲ 21.0%	20.79B▲ 128.9%	37.55B▲ 80.6%	5.29B▼ 85.9%	16.48B▲ 211.5%	15.44B▼ 6.3%	14.85B▲ 0%
Operating Margin %	27.39%	28.5%	18.24%	21.81%	25.58%	37.43%	8.89%	25.91%	24.67%	23.45%
Operating Income Growth %	0.82%	6.24%	-50.87%	20.96%	128.87%	80.58%	-85.91%	211.47%	-6.35%	-
EBITDA	20.66B	21.67B	13.31B	13.77B	25.98B	42.61B	11.58B	23.5B	20.34B	21B
EBITDA Margin %	39.32%	40.4%	32.32%	33.05%	31.97%	42.47%	19.45%	36.93%	32.51%	33.17%
EBITDA Growth %	3.14%	4.9%	-38.61%	3.46%	88.75%	64%	-72.82%	102.87%	-13.42%	-12.82%
D&A (Non-Cash Add-back)	6.27B	6.38B	5.79B	4.68B	5.19B	5.06B	6.29B	7.01B	4.91B	6.16B
EBIT	13.57B	13.2B	13.06B	8.49B	25.6B	35.97B	3.27B	11.11B	10.19B	10.79B
Net Interest Income	-879M	-983M	-1.35B	-1.38B	-1.25B	-987M	-585M	-2.55B	-2.07B	-2.11B
Interest Income	391M	333M	225M	73M	36M	251M	1.62B	545M	603M	575M
Interest Expense	1.27B	1.32B	1.57B	1.45B	1.29B	1.24B	2.21B	3.09B	2.67B	2.69B
Other Income/Expense	-2.09B	-3.4B	3.97B	-2.05B	3.52B	-2.82B	-4.23B	-8.46B	-7.92B	-6.94B
Pretax Income	12.3B▲ 0%	11.88B▼ 3.4%	11.48B▼ 3.4%	7.04B▼ 38.7%	24.31B▲ 245.5%	34.73B▲ 42.9%	1.06B▼ 97.0%	8.02B▲ 658.3%	7.52B▼ 6.3%	7.91B▲ 0%
Pretax Margin %	23.42%	22.15%	27.9%	16.89%	29.91%	34.61%	1.78%	12.61%	12.02%	12.49%
Income Tax	-9.05B	706M	618M	370M	1.85B	3.33B	-1.11B	-28M	-266M	384M
Effective Tax Rate %	-73.53%	5.94%	5.38%	5.26%	7.62%	9.58%	-105.29%	-0.35%	-3.54%	4.86%
Net Income	21.3B▲ 0%	11.15B▼ 47.7%	16.27B▲ 45.9%	9.16B▼ 43.7%	22.15B▲ 141.8%	31.36B▲ 41.6%	2.13B▼ 93.2%	8.02B▲ 276.0%	7.77B▼ 3.1%	7.49B▲ 0%
Net Margin %	40.55%	20.79%	39.52%	21.99%	27.25%	31.26%	3.58%	12.6%	12.42%	11.83%
Net Income Growth %	195.29%	-47.65%	45.91%	-43.72%	141.81%	41.62%	-93.2%	276%	-3.12%	-4.78%
Net Income (Continuing)	21.35B	11.18B	10.87B	6.67B	22.46B	31.4B	2.17B	8.05B	7.79B	7.52B
Discontinued Operations	-1M	10M	5.43B	2.53B	-268M	-1M	0	11M	25M	0
Minority Interest	348M	351M	303M	235M	262M	256M	274M	294M	299M	303M
EPS (Diluted)	3.52▲ 0%	1.87▼ 46.9%	2.87▲ 53.7%	1.63▼ 43.3%	3.88▲ 138.6%	5.47▲ 41.0%	0.37▼ 93.2%	1.41▲ 279.8%	1.36▼ 3.5%	1.31▲ 0%
EPS Growth %	200.58%	-46.94%	53.67%	-43.29%	138.58%	41.01%	-93.22%	279.85%	-3.55%	-5.05%
EPS (Basic)	3.57	1.90	2.92	1.65	3.95	5.59	0.38	1.42	1.36	-
Diluted Shares Outstanding	6.06B	5.98B	5.67B	5.63B	5.71B	5.73B	5.71B	5.7B	5.69B	5.73B
Basic Shares Outstanding	5.97B	5.87B	5.57B	5.55B	5.6B	5.61B	5.64B	5.66B	5.68B	5.69B
Dividend Payout Ratio	35.95%	71.53%	49.43%	92.15%	39.41%	28.64%	433.52%	118.6%	125.75%	-

PFE Balance Sheet

Pfizer Inc. (PFE) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	41.14B	49.93B	32.8B	35.07B	59.69B	51.26B	43.33B	50.36B	42.9B	42.82B
Cash & Short-Term Investments	19.99B	18.83B	9.65B	12.22B	31.07B	22.73B	12.69B	20.48B	13.6B	13.07B
Cash Only	1.34B	1.14B	1.12B	1.79B	1.94B	416M	2.85B	1.04B	1.14B	1.7B
Short-Term Investments	18.65B	17.69B	8.53B	10.44B	29.13B	22.32B	9.84B	19.43B	12.45B	11.37B
Accounts Receivable	11.27B	11.4B	9.51B	11.18B	15.74B	14.53B	15.54B	14.78B	11.87B	12.59B
Days Sales Outstanding	78.29	77.56	84.29	97.95	70.7	52.86	95.27	84.77	69.26	73.21
Inventory	7.58B	7.51B	7.07B	8.05B	9.06B	8.98B	10.19B	10.85B	10.65B	10.67B
Days Inventory Outstanding	175.32	171.19	204.37	249.49	96.08	85.72	127.31	181.84	209.46	209.03
Other Current Assets	2.3B	12.19B	6.58B	3.65B	3.82B	5.02B	4.91B	4.25B	6.77B	2.91B
Total Non-Current Assets	130.65B	109.5B	134.69B	119.16B	121.78B	145.94B	183.17B	163.04B	165.26B	164.8B
Property, Plant & Equipment	13.87B	13.38B	12.97B	13.74B	14.88B	16.27B	18.94B	18.39B	21.53B	19.4B
Fixed Asset Turnover	3.79x	4.01x	3.17x	3.03x	5.46x	6.17x	3.14x	3.46x	2.91x	3.22x
Goodwill	55.95B	53.41B	48.2B	49.56B	49.21B	51.38B	67.78B	68.53B	71.26B	71.41B
Intangible Assets	48.74B	35.21B	33.94B	28.34B	25.15B	43.37B	64.9B	55.41B	53.73B	52.56B
Long-Term Investments	7.01B	2.77B	20.15B	20.26B	21.53B	15.07B	15.37B	2.23B	1.74B	5.72B
Other Non-Current Assets	3.23B	2.8B	17.63B	4.57B	7.68B	13.16B	12.47B	9.82B	7.3B	37.8B
Total Assets	171.8B▲ 0%	159.42B▼ 7.2%	167.49B▲ 5.1%	154.23B▼ 7.9%	181.48B▲ 17.7%	197.21B▲ 8.7%	226.5B▲ 14.9%	213.4B▼ 5.8%	208.16B▼ 2.5%	207.62B▲ 0%
Asset Turnover	0.31x	0.34x	0.25x	0.27x	0.45x	0.51x	0.26x	0.30x	0.30x	0.30x
Asset Growth %	0.11%	-7.2%	5.06%	-7.92%	17.67%	8.67%	14.85%	-5.79%	-2.45%	-12.22%
Total Current Liabilities	30.43B	31.86B	37.3B	25.92B	42.67B	42.14B	47.79B	42.99B	36.98B	34.35B
Accounts Payable	4.66B	4.67B	3.89B	4.28B	5.58B	6.81B	6.71B	5.63B	5.24B	4.51B
Days Payables Outstanding	107.72	106.57	112.39	132.81	59.16	64.99	83.84	94.4	103.02	93.73
Short-Term Debt	9.94B	8.84B	16.19B	2.7B	2.24B	2.93B	10.35B	6.95B	3.48B	3.89B
Deferred Revenue (Current)	0	0	0	1.11B	3.07B	2.52B	2.7B	1.51B	784M	2.83B
Other Current Liabilities	13.32B	15.04B	14.14B	14.61B	28.27B	25.98B	23.32B	23.2B	18.32B	20.11B
Current Ratio	1.35x	1.57x	0.88x	1.35x	1.40x	1.22x	0.91x	1.17x	1.16x	1.16x
Quick Ratio	1.10x	1.33x	0.69x	1.04x	1.19x	1.00x	0.69x	0.92x	0.87x	0.87x
Cash Conversion Cycle	145.89	142.17	176.27	214.63	107.62	73.59	138.74	172.21	175.7	188.5
Total Non-Current Liabilities	69.71B	63.81B	66.84B	64.84B	61.34B	59.15B	89.42B	81.9B	84.4B	82.87B
Long-Term Debt	32.67B	32.91B	34.65B	35.57B	34.76B	31.93B	60.5B	57.41B	61.64B	60.56B
Capital Lease Obligations	-27B	-21.35B	1.03B	0	0	0	0	2.29B	2.29B	2.29B
Deferred Tax Liabilities	3.9B	3.7B	5.58B	4.06B	349M	1.02B	640M	2.12B	2.4B	9.76B
Other Non-Current Liabilities	33.15B	27.2B	26.54B	25.2B	26.24B	26.2B	28.28B	20.09B	18.07B	76.49B
Total Liabilities	100.14B	95.66B	104.15B	90.76B	104.01B	101.29B	137.21B	124.9B	121.39B	117.21B
Total Debt	42.61B	41.74B	50.84B	38.27B	37B	34.86B	70.84B	66.99B	67.42B	64.45B
Net Debt	41.26B	40.61B	49.72B	36.49B	35.05B	34.44B	67.99B	65.95B	66.27B	62.75B
Debt / Equity	0.59x	0.65x	0.80x	0.60x	0.48x	0.36x	0.79x	0.76x	0.78x	0.78x
Debt / EBITDA	2.06x	1.93x	3.82x	2.78x	1.42x	0.82x	6.12x	2.85x	3.31x	3.07x
Net Debt / EBITDA	2.00x	1.87x	3.74x	2.65x	1.35x	0.81x	5.87x	2.81x	3.26x	3.26x
Interest Coverage	10.69x	10.03x	8.30x	5.86x	19.83x	29.05x	1.48x	3.60x	3.82x	4.02x
Total Equity	71.66B▲ 0%	63.76B▼ 11.0%	63.45B▼ 0.5%	63.47B▲ 0.0%	77.46B▲ 22.0%	95.92B▲ 23.8%	89.29B▼ 6.9%	88.5B▼ 0.9%	86.78B▼ 1.9%	90.4B▲ 0%
Equity Growth %	19.75%	-11.02%	-0.49%	0.04%	22.04%	23.82%	-6.91%	-0.89%	-1.95%	-0.44%
Book Value per Share	11.83	10.67	11.18	11.27	13.57	16.73	15.64	15.53	15.26	15.77
Total Shareholders' Equity	71.31B	63.41B	63.14B	63.24B	77.2B	95.66B	89.01B	88.2B	86.48B	90.1B
Common Stock	464M	467M	468M	470M	473M	476M	478M	480M	481M	482M
Retained Earnings	85.29B	89.55B	97.67B	96.77B	103.39B	125.66B	118.35B	116.72B	114.61B	117.24B
Treasury Stock	-89.42B	-101.61B	-110.8B	-110.99B	-111.36B	-113.97B	-114.49B	-114.76B	-115.02B	-115.19B
Accumulated OCI	-9.32B	-11.28B	-11.64B	-11.69B	-5.9B	-8.3B	-7.96B	-7.84B	-8.07B	-7.2B
Minority Interest	348M	351M	303M	235M	262M	256M	274M	294M	299M	303M

PFE Cash Flow Statement

Pfizer Inc. (PFE) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	16.47B	15.83B	12.59B	14.4B	32.58B	29.27B	8.7B	12.74B	11.71B	11.71B
Operating CF Margin %	31.34%	29.5%	30.57%	34.58%	40.08%	29.17%	14.61%	20.03%	18.7%	-
Operating CF Growth %	3.58%	-3.9%	-20.46%	14.42%	126.2%	-10.17%	-70.27%	46.48%	-8.15%	27.46%
Net Income	21.36B	11.19B	16.3B	7.02B	22.46B	31.4B	2.17B	8.05B	7.75B	7.49B
Depreciation & Amortization	6.27B	6.38B	6.01B	4.78B	5.19B	5.06B	6.29B	7.01B	6.59B	6.59B
Stock-Based Compensation	840M	949M	718M	756M	1.18B	872M	525M	877M	0	676M
Deferred Taxes	-2.41B	-2.21B	614M	-1.47B	-4.29B	-3.76B	-3.44B	-2.1B	-2.13B	-1.48B
Other Non-Cash Items	-10.88B	437M	-7.03B	3.59B	-4.76B	150M	5.33B	1.97B	4.85B	-3.06B
Working Capital Changes	1.3B	-926M	-4.03B	-275M	12.8B	-4.46B	-2.17B	-3.07B	-5.35B	1.74B
Change in Receivables	259M	-644M	-742M	-1.25B	-3.81B	261M	347M	-109M	-263M	0
Change in Inventory	-357M	-717M	-1.05B	-736M	-1.13B	592M	6.2B	-854M	561M	0
Change in Payables	46M	431M	-564M	353M	1.24B	1.19B	-300M	-1.02B	-469M	0
Cash from Investing	-4.74B	4.53B	-3.94B	-4.27B	-22.55B	-15.78B	-32.28B	2.65B	-1.35B	-3.84B
Capital Expenditures	-2.22B	-2.2B	-2.59B	-2.79B	-2.71B	-3.24B	-3.91B	-2.91B	-2.63B	-2.5B
CapEx % of Revenue	4.22%	4.09%	6.3%	6.7%	3.34%	3.23%	6.56%	4.57%	4.2%	-
Acquisitions	-1B	154M	-10.86B	-621M	-12M	-23B	-43.43B	7.04B	-6.93B	-13.24B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	650M	133M	206M	813M	-306M	3.77B	-180M	0	165M	-904M
Cash from Financing	-13.04B	-20.44B	-8.48B	-9.65B	-9.82B	-14.83B	26.07B	-17.14B	-10.3B	-7.93B
Debt Issued (Net)	-941M	-935M	8.76B	-12.76B	-1.1B	-3.52B	35.95B	-7.16B	-74M	2.23B
Equity Issued (Net)	-5B	-10.94B	-8.87B	0	0	-2B	0	0	0	0
Dividends Paid	-7.66B	-7.98B	-8.04B	-8.44B	-8.73B	-8.98B	-9.25B	-9.51B	-9.77B	-9.78B
Share Repurchases	-5B	-12.2B	-8.87B	0	0	-2B	0	0	0	0
Other Financing	250M	-589M	-341M	11.55B	16M	-335M	-632M	-469M	-459M	-386M
Net Change in Cash	-1.25B▲ 0%	-206M▲ 83.6%	-50M▲ 75.7%	475M▲ 1050.0%	158M▼ 66.7%	-1.51B▼ 1058.9%	2.45B▲ 261.7%	-1.81B▼ 173.9%	99M▲ 105.5%	275M▲ 0%
Free Cash Flow	14.25B▲ 0%	13.63B▼ 4.4%	9.99B▼ 26.7%	11.61B▲ 16.2%	29.87B▲ 157.2%	26.03B▼ 12.8%	4.79B▼ 81.6%	9.84B▲ 105.2%	9.08B▼ 7.7%	9.48B▲ 0%
FCF Margin %	27.12%	25.41%	24.27%	27.88%	36.74%	25.95%	8.05%	15.46%	14.5%	14.98%
FCF Growth %	2.52%	-4.36%	-26.68%	16.19%	157.23%	-12.85%	-81.59%	105.2%	-7.72%	-15.47%
FCF per Share	2.35	2.28	1.76	2.06	5.23	4.54	0.84	1.73	1.60	1.60
FCF Conversion (FCF/Net Income)	0.77x	1.42x	0.77x	1.57x	1.47x	0.93x	4.08x	1.59x	1.51x	1.27x
Interest Paid	1.52B	1.31B	1.59B	1.64B	1.47B	1.44B	2.21B	3.23B	0	1.7B
Taxes Paid	2.49B	3.65B	3.66B	3.15B	7.43B	7.87B	3.15B	3.6B	0	3.59B

PFE Key Ratios

Pfizer Inc. (PFE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	32.4%	16.47%	25.59%	14.43%	31.43%	36.18%	2.3%	9.02%	8.87%	8.34%
Return on Invested Capital (ROIC)	10.22%	10.55%	5.18%	6.39%	14.68%	23.19%	2.76%	7.93%	7.53%	7.53%
Gross Margin	69.97%	70.16%	69.34%	71.74%	57.67%	61.89%	50.95%	65.77%	70.33%	69.35%
Net Margin	40.55%	20.79%	39.52%	21.99%	27.25%	31.26%	3.58%	12.6%	12.42%	11.83%
Debt / Equity	0.59x	0.65x	0.80x	0.60x	0.48x	0.36x	0.79x	0.76x	0.78x	0.78x
Interest Coverage	10.69x	10.03x	8.30x	5.86x	19.83x	29.05x	1.48x	3.60x	3.82x	4.02x
FCF Conversion	0.77x	1.42x	0.77x	1.57x	1.47x	0.93x	4.08x	1.59x	1.51x	1.27x
Revenue Growth	-0.53%	2.1%	-23.25%	1.16%	95.16%	23.43%	-40.64%	6.84%	-1.65%	1.36%

PFE SEC Filings & Documents

Pfizer Inc. (PFE) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Apr 27, 2026·SEC

Material company update

Feb 3, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 5, 2025·SEC

PFE Frequently Asked Questions

Pfizer Inc. (PFE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Pfizer Inc. (PFE) reported $63.31B in revenue for fiscal year 2025. This represents a 460% increase from $11.31B in 1996.

Pfizer Inc. (PFE) saw revenue decline by 1.6% over the past year.

Yes, Pfizer Inc. (PFE) is profitable, generating $7.49B in net income for fiscal year 2025 (12.4% net margin).

Dividend & Returns

Yes, Pfizer Inc. (PFE) pays a dividend with a yield of 6.50%. This makes it attractive for income-focused investors.

Pfizer Inc. (PFE) has a return on equity (ROE) of 8.9%. This is below average, suggesting room for improvement.

Pfizer Inc. (PFE) generated $9.48B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More PFE

Pfizer Inc. (PFE) financial analysis — history, returns, DCA and operating performance tools

Full PFE Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Pfizer Inc.(PFE)Earnings, Financials & Key Ratios

PFE Key Insights

✓Strengths

✗Weaknesses

PFE Price & Volume

PFE Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

PFE Recent Earnings

PFE Peer Comparison

Compare PFE vs Peers

vs JNJ

vs LLY

Compare Top 5

PFE Income Statement

PFE Balance Sheet

PFE Cash Flow Statement

PFE Key Ratios

PFE SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

PFE Frequently Asked Questions

Explore More PFE

Full PFE Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation